Wed, Oct 22, 2014, 7:29 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • penny.dung penny.dung Jun 25, 2014 5:52 PM Flag

    DUE DILIGENCE on What ONCS Has to Offer:

    "Our company was incorporated under the laws of Nevada on February 8, 2008 as Netventory Solutions Inc."
    ONCS was an internet company. That didn't work out so they morphed into a biotech company.
    How did they do that?

    "On March 14, 2011, we entered into an Asset Purchase Agreement with Inovio to acquire certain assets from Inovio related to certain non-DNA vaccine technology and intellectual property relating to selective electrochemical tumor ablation (referred to as OMS)."

    What did ONCS acquire from Inovio?
    THIS IS IMPORTANT:
    "Inovio granted to us a non-exclusive, worldwide license to certain non-SECTA technology patents held by Inovio" ... "Because the license is non-exclusive, Inovio may use its technology to compete with us. In addition, there are no restrictions on Inovio’s ability to license their technology to others."
    SO WHAT DID ONCS ACQUIRE? ABSOLUTELY NOTHING!

    THIS IS EVEN MORE IMPORTANT:
    "Acquisition of the OMS tech. included an extensive clinical database from two Phase III clinical trials that were halted before enrollment was completed. In 2007, these two Phase III clinical trials, HNBE-01 and HNBE-02, which were designed to evaluate the use of the NeoPulse technology as a treatment for resectable recurrent and second primary squamous cell carcinomas of the head and neck were halted as a result of a recommendation from the Data Monitoring Committee (DMC). The DMC cited concerns regarding efficacy and safety, including mortality rates and enrollment futility. In the DMC’s opinion, the totality of data for these recurrent head and neck cancer studies suggested an unfavorable benefit-to-risk profile for the NeoPulse arm relative to the surgery arm ... enrollment for both studies were halted, however the treated patients were followed up to two years to further evaluate safety and efficacy, and the clinical trials were not reinitiated."
    SO ONCS ACQUIRED FAILED TECHNOLOGY THAT WAS WRITTEN OFF IN 2007 BECAUSE OF LACK OF EFFICACY & HIGH MORTALITY.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ONCS
0.450.00(-0.99%)Oct 22 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.